Skip to content

MaxiFlex Fiber Optic Energy Delivery System

by Technology Delivery Systems, Inc.

510(k) K013300

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK013300 Date16 Apr 2002ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA Product Code
GEX
Device Class
Class II
Regulation
21 CFR Part 878.4810
Advisory Committee
General, Plastic Surgery
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The MaxiFlex Fiber Optic Energy Delivery System is a fiber optic device classified under 21 CFR 878.4810, designed for the delivery of laser energy. It facilitates soft tissue procedures including ablation, incision, excision, vaporization, and coagulation across general surgery, dermatology, intraoral, orthopaedic, maxillofacial, and cosmetic applications.

This system is intended for single-use in controlled clinical settings and requires compatibility with approved laser sources. Supplied sterile, it is regulated under FDA 510(k) clearance (K013300) and adheres to product code GEX. Storage and handling must comply with manufacturer guidelines to maintain sterility and performance.

Other devices from Technology Delivery Systems, Inc.

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What types of medical procedures can the MaxiFlex Fiber Optic Energy Delivery System be used for?

    The MaxiFlex Fiber Optic Energy Delivery System is designed for soft tissue procedures across multiple specialties, including general surgery, dermatology, intraoral, orthopaedic, maxillofacial, and cosmetic applications. It facilitates laser-based actions like ablation, incision, excision, vaporization, and coagulation, depending on the compatible laser source used.

  • Is the MaxiFlex Fiber Optic Energy Delivery System intended for single-use or reusable applications?

    The MaxiFlex Fiber Optic Energy Delivery System is explicitly intended for single-use in controlled clinical settings. This design ensures patient safety and maintains performance consistency, as reuse is not supported by the manufacturer.

  • How should the MaxiFlex Fiber Optic Energy Delivery System be stored to ensure sterility and functionality?

    The system is supplied sterile, so storage must follow the manufacturer’s guidelines to preserve sterility and performance. Proper handling—such as keeping it in its original packaging, avoiding contamination, and adhering to recommended environmental conditions—is critical to maintaining its integrity for clinical use.

  • What laser sources is the MaxiFlex Fiber Optic Energy Delivery System compatible with?

    The MaxiFlex Fiber Optic Energy Delivery System requires compatibility with approved laser sources to function effectively. While the specific laser types aren’t detailed here, the device is designed to work with standard laser systems used for soft tissue procedures, ensuring energy delivery for ablation, coagulation, or other intended actions.

  • How was the FDA clearance for the MaxiFlex Fiber Optic Energy Delivery System determined?

    The MaxiFlex Fiber Optic Energy Delivery System received FDA clearance through a 510(k) submission (K013300), with a decision classification of *Substantially Equivalent* (SESE). This means the FDA determined it is as safe and effective as a legally marketed predicate device, based on the manufacturer’s technical documentation and testing.